|
|
|
Volumn 25, Issue 5, 2011, Pages
|
|
HER2-targeted therapies: How far we've comeand where we're headed
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTHRACYCLINE DERIVATIVE;
BEVACIZUMAB;
CAPECITABINE;
EPIDERMAL GROWTH FACTOR RECEPTOR 2;
LAPATINIB;
LETROZOLE;
NERATINIB;
PERTUZUMAB;
TRASTUZUMAB;
TRASTUZUMAB EMTANSINE;
TUMOR MARKER;
ADVANCED CANCER;
BREAST CANCER;
CANCER ADJUVANT THERAPY;
CANCER COMBINATION CHEMOTHERAPY;
CANCER RECURRENCE;
CANCER STAGING;
CANCER SURVIVAL;
CARDIOTOXICITY;
CARDIOVASCULAR RISK;
CLINICAL PRACTICE;
DRUG DOSE SEQUENCE;
DRUG EFFECT;
DRUG MECHANISM;
DRUG MONITORING;
DRUG TARGETING;
DRUG TOLERABILITY;
EARLY CANCER;
FLUORESCENCE IN SITU HYBRIDIZATION;
GENE OVEREXPRESSION;
HIGH RISK PATIENT;
HUMAN;
IMMUNOCHEMISTRY;
METASTASIS;
MOLECULARLY TARGETED THERAPY;
MONOTHERAPY;
NOTE;
OUTCOME ASSESSMENT;
PATIENT SELECTION;
PRACTICE GUIDELINE;
PREDICTION;
PROGNOSIS;
RISK FACTOR;
|
|
EID: 79956197640
PISSN: 08909091
EISSN: 08909091
Source Type: Journal
DOI: None Document Type: Note |
|
Times cited : (4)
|
|
References (0)
|
